Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...

When Roy Bradley was told he had cancer in his lungs and liver, his first thought was he couldn't face chemotherapy and ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...

GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...